Page last updated: 2024-11-04

beclomethasone dipropionate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

beclomethasone dipropionate : A steroid ester comprising beclomethasone having propionyl groups at the 17- and 21-positions. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID21700
CHEMBL ID1200500
CHEBI ID3002
SCHEMBL ID6890
MeSH IDM0002259

Synonyms (178)

Synonym
AC-2159
MLS002154034 ,
smr001233361
BRD-K97810537-001-03-7
BPBIO1_000957
PRESTWICK_990
NCGC00179392-01
PRESTWICK2_000855
BSPBIO_000869
kw-053
clenil
becloturmant
beclate
sch 18020w
9-chloro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione 17,21-dipropionate
beclomethasone dipropionate [usan]
pregna-1,4-diene-3,20-dione, 9-chloro-11-hydroxy-16-methyl-17,21-bis(1-oxopropoxy)-, (11beta,16beta)-
aldecina
beclocort nasel
atomase
qvar 40
qvar 80
vanceril double strength
propaderm forte
rhinosol
inalone o
turbinal
spir
inalone r
alanase
beclomet nasal
qvar
benconase
einecs 226-886-0
rhino clenil
aldecine
pregna-1,4-diene-3,20-dione, 9-chloro-16-beta-methyl-11-beta,17,21-trihydroxy-, 17,21-dipropionate
respocort
beconase aq
C07813
5534-09-8
beclometasone dipropionate
beclomethasone dipropionate
aerobec
beclomet
(11beta,16beta)-9-chloro-11-hydroxy-16-methyl-17,21-bis(1-oxopropoxy)pregna-1,4-diene-3,20-dione
inalone
becloforte
beclorhinol
viarex
(11beta,16beta)-9-chloro-11-hydroxy-16-methyl-3,20-dioxopregna-1,4-diene-17,21-diyl dipropanoate
sanasthmyl
becodisks
9-chloro-16beta-methyl-11beta,17,21-trihydroxypregna-1,4-diene-3,20-dione 17,21-dipropionate
becloval
CHEBI:3002 ,
beconasol
beclometasone 17,21-dipropionate
vancenase
rino-clenil
sanasthmax
entyderma
propaderm
aldecin
anceron
becotide
9-chloro-11beta-hydroxy-16beta-methylpregna-1,4-diene-3,20-dione 17,21-dipropionate
beconase
clenil-a
beclacin
korbutone
beclovent
vanceril
viarox
DB00394
D00689
beclomethasone dipropionate (usp)
qnasl (tn)
vanceril (tn)
beclometasone dipropionate (jp17)
beclovent (tn)
PRESTWICK3_000855
PRESTWICK0_000855
PRESTWICK1_000855
SPBIO_002790
dipropionate, beclomethasone
ventolair
beclazone
sgx-203
sgx-202
sch 8020w
sch-18020w
CHEMBL1200500
sgx-201
nsc-755901
[2-[(8s,9r,10s,11s,13s,14s,16s,17r)-9-chloro-11-hydroxy-10,13,16-trimethyl-3-oxo-17-propanoyloxy-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] propanoate
HMS1570L11
cpd001233361
NCGC00094596-03
HMS2097L11
HMS3259H03
cas-5534-09-8
dtxsid3048730 ,
dtxcid6028656
tox21_113168
AKOS015951275
HMS2235O23
beclomethasone dipropionate [usan:usp]
unii-5b307s63b2
beclazone 250
qnasl
beclometasone dipropionato
menaderm
5b307s63b2 ,
nsc 755901
betamethasone dipropionate impurity e
orbeshield
beclometasone dipropionate [jan]
beclometasone dipropionate anhydrous
orbec
beclomethasone dipropionate [orange book]
beclomethasone dipropionate [vandf]
beclometasoni dipropionas [who-ip latin]
beclomethasone dipropionate [mi]
beclomethasone dipropionate [usp monograph]
belchlorhinol
beclometasone dipropionate [who-dd]
beclomethasone dipropionate [usp impurity]
beclometasone dipropionate [who-ip]
nasobec
topster
beclomethasone dipropionate [usp-rs]
clenil a
sanasthymyl
pregna-1,4-diene-3,20-dione, 9-chloro-11-hydroxy-16-methyl-17,21-bis(1-oxopropoxy)-, (11.beta.,16.beta.)-
beclometasone dipropionate, anhydrous [ep impurity]
beclomethasone 17,21-dipropionate
trimbow component beclomethasone dipropionate
beclometasone dipropionate [ep monograph]
beclomethasone 17,21-diproprionate
beclometasone dipropionate, anhydrous
S3078 ,
[(8s,9r,10s,11s,13s,14s,16s,17r)-9-chloro-11-hydroxy-10,13,16-trimethyl-3-oxo-17-(2-propanoyloxyacetyl)-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] propanoate
gtpl5894
CCG-220855
CS-1503
HY-13571A
NC00610
SCHEMBL6890
9-chloro-11.beta.,17,21-trihydroxy-16.beta.-methylpregna-1,4-diene-3,20-dione 17,21-dipropionate
B4464
2-[(1r,2s,10s,11s,13s,14r,15s,17s)-1-chloro-17-hydroxy-2,13,15-trimethyl-5-oxo-14-(propanoyloxy)tetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-dien-14-yl]-2-oxoethyl propanoate
beclomethasone dipropionate, anhydrous, european pharmacopoeia (ep) reference standard
beclomethasone dipropionate, analytical standard, for drug analysis
beclomethasone dipropionate, united states pharmacopeia (usp) reference standard
beclometasone dipropionate for peak identification, european pharmacopoeia (ep) reference standard
beclomethasone dipropionate, pharmaceutical secondary standard; certified reference material
beclometasone dipropionate for system suitability, european pharmacopoeia (ep) reference standard
HMS3714L11
beclometasone (beclomethasone) dipropionate, british pharmacopoeia (bp) assay standard
Q421475
BRD-K97810537-001-13-6
beclomethasone-dipropionate
9alpha-chloro-16beta-methyl-3,20-dioxo-1,4-pregnadiene-11beta,17,21-triol 17,21-dipropionate
beclomethasone dipropionate anhydrous
beclomethazone dipropionate
D89082
(8s,9r,10s,11s,13s,14s,16s,17r)-9-chloro-11-hydroxy-10,13,16-trimethyl-3-oxo-17-[2-(propionyloxy)acetyl]-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3h-cyclopenta[a]phenanthren-17-yl propionate
beclomethasone dipropionate (usan:usp)
beclomethasone dipropionate (usp impurity)
beclomethasone dipropionate (usp-rs)
qvar redihaler
beclometasone dipropionate (ep monograph)
beclometasone dipropionate, anhydrous (ep impurity)
beclomethasone dipropionate (usp monograph)
beclomethasone dipropionate hfa
2-[(1r,2s,3as,3bs,9as,9br,10s,11as)-9b-chloro-10-hydroxy-2,9a,11a-trimethyl-7-oxo-1-(propanoyloxy)-1h,2h,3h,3ah,3bh,4h,5h,7h,9ah,9bh,10h,11h,11ah-cyclopenta[a]phenanthren-1-yl]-2-oxoethyl propanoate
EN300-7480875

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36

Pharmacokinetics

ExcerptReferenceRelevance
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
anti-inflammatory drugA substance that reduces or suppresses inflammation.
anti-asthmatic drugA drug used to treat asthma.
prodrugA compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug.
anti-arrhythmia drugA drug used for the treatment or prevention of cardiac arrhythmias. Anti-arrhythmia drugs may affect the polarisation-repolarisation phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibres.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (9)

ClassDescription
steroid ester
enoneAn alpha,beta-unsaturated ketone of general formula R(1)R(2)C=CR(3)-C(=O)R(4) (R(4) =/= H) in which the C=O function is conjugated to a C=C double bond at the alpha,beta position.
20-oxo steroidAn oxo steroid carrying an oxo group at position 20.
11beta-hydroxy steroidAny 11-hydroxy steroid in which the hydroxy group at position 11 has beta- configuration.
propanoate esterAny carboxylic ester where the carboxylic acid component is propionic acid.
corticosteroidA natural or synthetic analogue of the hormones secreted by the adrenal gland.
glucocorticoidGlucocorticoids are a class of steroid hormones that regulate a variety of physiological processes, in particular control of the concentration of glucose in blood.
3-oxo-Delta(1),Delta(4)-steroidA 3-oxo-Delta(1) steroid containing an additional double bond between positions 4 and 5.
chlorinated steroidA steroid which is substituted with one or more chlorine atoms in any position.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (20)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency5.62340.044717.8581100.0000AID485294; AID485341
glp-1 receptor, partialHomo sapiens (human)Potency31.62280.01846.806014.1254AID624417
thioredoxin reductaseRattus norvegicus (Norway rat)Potency79.43280.100020.879379.4328AID588453
TDP1 proteinHomo sapiens (human)Potency20.45180.000811.382244.6684AID686978; AID686979
AR proteinHomo sapiens (human)Potency8.22030.000221.22318,912.5098AID743035; AID743036; AID743040; AID743042; AID743053; AID743054; AID743063
isocitrate dehydrogenase 1, partialHomo sapiens (human)Potency35.48136.309627.099079.4328AID602179
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency0.00320.000214.376460.0339AID720691; AID720692; AID720719
estrogen nuclear receptor alphaHomo sapiens (human)Potency0.03410.000229.305416,493.5996AID743075; AID743080; AID743091
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency25.84130.001019.414170.9645AID743094; AID743140
aryl hydrocarbon receptorHomo sapiens (human)Potency10.59090.000723.06741,258.9301AID743085; AID743122
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency2.66030.001723.839378.1014AID743083
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency0.00580.00419.984825.9290AID504444
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency29.84930.000323.4451159.6830AID743065
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency79.43280.425612.059128.1838AID504891
urokinase-type plasminogen activator precursorMus musculus (house mouse)Potency2.81840.15855.287912.5893AID540303
plasminogen precursorMus musculus (house mouse)Potency2.81840.15855.287912.5893AID540303
urokinase plasminogen activator surface receptor precursorMus musculus (house mouse)Potency2.81840.15855.287912.5893AID540303
gemininHomo sapiens (human)Potency0.23110.004611.374133.4983AID624297
Guanine nucleotide-binding protein GHomo sapiens (human)Potency15.84891.995325.532750.1187AID624288
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
TPA: protein transporter TIM23Saccharomyces cerevisiae S288CIC50 (µMol)14.90000.880010.503632.9000AID493002
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (5)

Processvia Protein(s)Taxonomy
negative regulation of inflammatory response to antigenic stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
renal water homeostasisGuanine nucleotide-binding protein GHomo sapiens (human)
G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein GHomo sapiens (human)
regulation of insulin secretionGuanine nucleotide-binding protein GHomo sapiens (human)
cellular response to glucagon stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (2)

Processvia Protein(s)Taxonomy
G protein activityGuanine nucleotide-binding protein GHomo sapiens (human)
adenylate cyclase activator activityGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (50)

Assay IDTitleYearJournalArticle
AID629917Therapeutic index, ratio of ED20 for thymolysis to ED70 for forced vital capacity in ovalbumin-challenged Brown-Norway rat2011Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21
Steroidal C-21 mercapto derivatives as dissociated steroids: discovery of an inhaled dissociated steroid.
AID136377Percentage systemic effect to assess the degree of absorption was measured at 2.5 ug/mouse1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Synthesis and antiinflammatory activity of novel 12 beta-substituted analogues of betamethasone.
AID136374Percentage systemic effect to assess the degree of absorption was measured 75 ug/mouse1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Synthesis and antiinflammatory activity of novel 12 beta-substituted analogues of betamethasone.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID724419Antiinflammatory activity against ovalbumin-induced airway allergic Brown-Norway rat model assessed as decrease of neutrophils in bronchoalveolar lavage fluid at 11 mg/kg administered intranasally as dry powder measured on day 29 after ovalbumin challenge2013Bioorganic & medicinal chemistry, Jan-01, Volume: 21, Issue:1
Macrolactonolides: a novel class of anti-inflammatory compounds.
AID127966ED100 of was measured in the TPA induced mouse ear edema assay.1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Synthesis and antiinflammatory activity of novel 12 beta-substituted analogues of betamethasone.
AID135523Systemic Antiinflammatory activity was measured in the TPA induced mouse ear edema assay at 75 ug/mouse1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Synthesis and antiinflammatory activity of novel 12 beta-substituted analogues of betamethasone.
AID135516Systemic Antiinflammatory activity was measured in the TPA induced mouse ear edema assay at 2.5 ug/mouse1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Synthesis and antiinflammatory activity of novel 12 beta-substituted analogues of betamethasone.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID91225Antiinflammatory activity measured by using McKenzie-Stoughton human vasoconstrictor assay; Potent1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Computer-aided studies of the structure-activity relationships between the structure of some steroids and their antiinflammatory activity.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID135533Topical Antiinflammatory activity was measured in the TPA induced mouse ear edema assay at 75 ug/mouse.1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Synthesis and antiinflammatory activity of novel 12 beta-substituted analogues of betamethasone.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID222315Stability after incubation with human lung S9 (at 37 degree C)2000Journal of medicinal chemistry, Jan-13, Volume: 43, Issue:1
Selective plasma hydrolysis of glucocorticoid gamma-lactones and cyclic carbonates by the enzyme paraoxonase: an ideal plasma inactivation mechanism.
AID23842Stability after incubation with human plasma (at 37 degree C)2000Journal of medicinal chemistry, Jan-13, Volume: 43, Issue:1
Selective plasma hydrolysis of glucocorticoid gamma-lactones and cyclic carbonates by the enzyme paraoxonase: an ideal plasma inactivation mechanism.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID724193Antiinflammatory activity against ovalbumin-induced airway allergic Brown-Norway rat model assessed as decrease of eosinophils in bronchoalveolar lavage fluid at 11 mg/kg administered intranasally as dry powder measured on day 29 after ovalbumin challenge2013Bioorganic & medicinal chemistry, Jan-01, Volume: 21, Issue:1
Macrolactonolides: a novel class of anti-inflammatory compounds.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID135529Topical Antiinflammatory activity was measured in the TPA induced mouse ear edema assay at 25 ug/mouse.1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Synthesis and antiinflammatory activity of novel 12 beta-substituted analogues of betamethasone.
AID136372Percentage systemic effect to assess the degree of absorption was measured 25 ug/mouse1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Synthesis and antiinflammatory activity of novel 12 beta-substituted analogues of betamethasone.
AID135511Atrophogenicity potency was observed in mouse at 75 ug/mouse.1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Synthesis and antiinflammatory activity of novel 12 beta-substituted analogues of betamethasone.
AID135518Systemic Antiinflammatory activity was measured in the TPA induced mouse ear edema assay at 25 ug/mouse1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Synthesis and antiinflammatory activity of novel 12 beta-substituted analogues of betamethasone.
AID140736Skin thickness of mouse was measured at 75 ug/mouse1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Synthesis and antiinflammatory activity of novel 12 beta-substituted analogues of betamethasone.
AID90104Potency relative to fluocinolone 16,17-acetonide in the human vasoconstictor test1983Journal of medicinal chemistry, Mar, Volume: 26, Issue:3
Structure-activity relationships in the antiinflammatory steroids: a pattern-recognition approach.
AID724385Antiinflammatory activity against ovalbumin-induced airway allergic Brown-Norway rat model assessed as decrease of macrophages in bronchoalveolar lavage fluid at 11 mg/kg administered intranasally as dry powder measured on day 29 after ovalbumin challenge2013Bioorganic & medicinal chemistry, Jan-01, Volume: 21, Issue:1
Macrolactonolides: a novel class of anti-inflammatory compounds.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID135527Topical Antiinflammatory activity was measured in the TPA induced mouse ear edema assay at 2.5 ug/mouse.1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Synthesis and antiinflammatory activity of novel 12 beta-substituted analogues of betamethasone.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1345635Human ADGRG3 (Adhesion Class GPCRs)2012FEBS letters, Apr-24, Volume: 586, Issue:8
Signaling property study of adhesion G-protein-coupled receptors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (22)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (9.09)18.7374
1990's1 (4.55)18.2507
2000's3 (13.64)29.6817
2010's14 (63.64)24.3611
2020's2 (9.09)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (4.55%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other21 (95.45%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]